Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 16 May 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Planned primary completion date changed from 1 May 2016 to 1 Jun 2018.
- 28 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2018.